Peresolimab ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05516758 (ClinicalTrials.gov) | August 31, 2022 | 24/8/2022 | A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis | A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis | Rheumatoid Arthritis;Arthritis;Joint Diseases;Musculoskeletal Diseases;Rheumatic Diseases;Connective Tissue Diseases;Autoimmune Diseases;Immune System Diseases | Drug: Peresolimab;Drug: Placebo | Eli Lilly and Company | NULL | Recruiting | 18 Years | N/A | All | 420 | Phase 2 | United States;Argentina;Canada;China;Greece;Hungary;Italy;Japan;Mexico;Poland;Puerto Rico;Spain |